- Home
- FTFT vs NCNA Comparison
FTFT vs NCNA Comparison
Compare FTFT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTFT | NCNA |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.8M |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FTFT | NCNA |
|---|---|---|
| Price | $1.39 | $1.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 29.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,158,125.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.03 |
| 52 Week High | $4.03 | $10.00 |
Technical Indicators
Market Signals| Indicator | FTFT | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 36.81 |
| Support Level | $1.29 | $0.05 |
| Resistance Level | $1.60 | $2.27 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 28.79 | 18.42 |
Price Performance
Historical ComparisonAbout FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.